医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Fresenius Medical Care Demonstrates Commitment to Renal Education With Opening of Asia Pacific Education Center

2019年06月25日 PM08:14
このエントリーをはてなブックマークに追加


 

MAKATI, Philippines

Fresenius Medical Care, the world’s largest provider of dialysis products and services, today celebrated the opening of its new dialysis learning hub: The Fresenius Medical Care Asia Pacific Education Center.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190625005528/en/

Fresenius Medical Care today celebrated the opening of its new dialysis learning hub: The Fresenius Medical Care Asia Pacific Education Center. (Photo: Business Wire)

Fresenius Medical Care today celebrated the opening of its new dialysis learning hub: The Fresenius Medical Care Asia Pacific Education Center. (Photo: Business Wire)

With the worldwide demand for dialysis projected to more than double by 2030, and with most of that growth coming from Asia1, there is an urgent need for health care professionals to access education that can advance their dialysis knowledge and skills. Through the new Philippines-based center, clinicians and technicians who provide renal care throughout the Asia Pacific region will be able to access Fresenius Medical Care’s high standard of dialysis training, creating a new benchmark for training in the region.

For over two decades, Fresenius Medical Care has been supporting people in the Asia Pacific region who are living with chronic kidney disease (CKD). This is achieved through the provision of dialysis products and services and high-quality education of the employees who deliver life-sustaining dialysis care. Having offered this education to their own staff and customers for over 20 years, the new center will enable this same high standard of education to be shared with the wider dialysis community.

Speaking at the center opening, Dr Michael Etter – Senior Vice President, Medical Affairs, Fresenius Medical Care Asia Pacific – recognized that access to the right training will allow dialysis staff to develop their skills so they can continue to provide high standards of patient-centerd care: “The Asia Pacific Education Center utilises certified trainers and offers professional training that comprises of classroom education and practical skills simulation. Through this, we aim to reinforce the standard for training that we have been advocating in the Asia Pacific region, and by transferring this knowledge to the health care professionals, patients hopefully will be the ultimate beneficiaries”.

The new center will offer over 20 different education programmes for both renal nurses and technical staff, catering for varying backgrounds and levels of knowledge. The programmes focus on both practical and simulation learning and encourage problem-solving that teaches students to think more critically and to practise vital clinical decision-making skills.

The center’s state-of-the-art environment will foster learning using advanced equipment in a fully functional clinical training area. Designed to simulate an innovative clinical environment, the center includes 18 dialysis machines that facilitate training across a range of different therapy areas used in different countries – from chronic hemodialysis, to home dialysis and nutrition management systems – through to a fully functional water treatment system.

Ms Stephanie Franco – Managing Director, Fresenius Medical Care, Philippines – highlighted the importance of this investment in medical education for both the wider region and the local health care community: “The Philippines’ central location in Asia Pacific makes it an ideal hub for offering excellence in dialysis education throughout the region”, she said. “It will provide the opportunity for local renal nurses and technicians to upskill in a country where one person develops renal failure every hour.2 This significant investment from Fresenius Medical Care demonstrates the company’s commitment to dialysis nurses, technicians and patients in both the Philippines and throughout the Asia Pacific region.”

References

  1. Liyanage T et al. Worldwide access to treatment for end-stage kidney disease: a systematic review. www.thelancet.com Published online 13 March 2015. http://dx.doi.org/10.1016/S0140-6736(14)61601-9. Accessed 19 June 2019.
  2. National Kidney and Transplant Institute, Philippines. Kidney Health Plus. Available from http://www.nkti.gov.ph/index.php/patients-and-visitors/kidney-health-plus. Accessed 19 June 2019.

ABOUT FRESENIUS MEDICAL CARE

Fresenius Medical Care is the world’s largest provider of products and services for individuals with renal diseases of which around 3.4 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,971 dialysis clinics, Fresenius Medical Care provides dialysis treatments for 336,716 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Along with its core business, the company provides related medical services in the field of Care Coordination. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).

For more information, please visit www.freseniusmedicalcare.asia

DISCLAIMER

This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA’s reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190625005528/en/

CONTACT

Dr Alexandra Villar:

Alexandra.Villar@fmc-asia.com

 

同じカテゴリーの記事 

  • La Jolla Institute for Immunology and RevolKa started a Research Collaboration
  • U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
  • ESCMID Global 2024: Shionogi presents real-world data demonstrating efficacy of Fetcroja® / Fetroja® (cefiderocol) in critically ill patients with certain difficult-to-treat bacterial infections
  • Renesas’ New FemtoClock™ 3 Timing Solution Delivers Industry’s Lowest Power and Leading Jitter Performance of 25fs-rms
  • 成人向け予防接種プログラムは初期投資の19倍もの社会経済的価値をもたらすとの新レポートを発表